

## CASE STUDY

The site has set a benchmark for world-class design and development in medical devices, establishing a centre of excellence for automation and assembly to deliver a portfolio that drives innovation and growth for the long term. It will be the location for production of our recently launched, next generation auto-injector Aidaptus®. Compatible with either a 1mL or 2.25mL prefilled syringe, Aidaptus features a minimal number of change parts, in the same base device, making it a very flexible and intuitive device for drug delivery. Furthermore, the facility will be home to the manufacturing of our pioneering springless safety syringe Unisafe® and the latest lancets for blood sampling.



Owen Mumford is dedicated to improving the quality of life for patients worldwide. Our product portfolio, which includes devices for diabetes care, auto-injection, and blood sampling, showcases our expertise in creating solutions that meet the specific needs of healthcare providers and patients alike. Our commitment to the Healthcare and Life Sciences (HLS) sector is further evidenced by our continual investment in research and development, aiming to address the evolving challenges in healthcare with cutting-edge technology and design.

For over 70 years we have evolved our manufacturing processes across our operations, both worldwide and especially in the UK, whilst refining our supply chain. We adopt the latest in high speed, high volume assembly line technology, utilising fully automated assembly equipment, 100% quality checks are maintained in a clean-room environment and we run our own in-house injection moulding equipment. All of this delivers peace of mind to our customers, ensuring that delivery of life-enhancing medication is uninterrupted and guarantees traceability. Operating in such a heavily regulated industry, all our operations are GMP compliant.



By investing £14 million into the site and the advanced manufacturing technologies, we aim to not only address the immediate market needs but also solidify ourselves as a leader within the medical device industry. This strategic move aligns with the company's 2030 vision to grow profitably and make a positive difference to our customers, our users, our associates and our environment. The Witney facility not only signifies a commitment to quality and efficiency but also serves as a platform for Owen Mumford to explore and embark on new and exciting projects, demonstrating the company's dedication to continuous improvement.

As a global business and significant local employer, we have a commitment to carry out our business responsibly across all our markets, however, due to our roots within Oxfordshire, the importance of our local community plays a markedly special role. That is why we are especially proud to say that our Witney site was constructed, right in our back garden, with sustainability in mind from the offset. It was crucial that construction caused minimal impact to the surrounding environment and eco-system, and so we are pleased that the building is set to be included in the top 25 percent of buildings assessed through the Building Research Establishment Environmental Assessment Method (BREEAM).




The BREEAM certification recognises the highest levels of environmental, social and economic sustainability performance, requiring us to adhere to environmentally conscious planning, including consideration for the biodiversity of the site.

At the start of construction, we worked in conjunction with sustainability and conservation specialists to best incorporate bat and bird boxes into the building's design, alongside the integration of hedgehog gates and nature routes to ensure habitat connectivity and mitigate disturbance to local wildlife. One of the key ways in which we met sustainability targets during the build phase was through our disposal of construction waste, with 97 percent of it being diverted from landfill. Additionally, to maintain our sustainable practices, the site is using 100 percent renewable energy, with part of that being supplied by our own solar panels that generated 21,000 kWh last year. Following our other UK sites, 12 electronic charging points have been installed for EV users.

Further to this, we donated to a local charity, the Trust for Oxfordshire's Environment (TOE), as part of the responsible development process.

By donating to this reputable trust, we helped to deliver a biodiversity uplift project within the Oxfordshire region and, as a result, our site was awarded with a Biodiversity Net Gain agreement. The project in question is a grassland creation initiative near Enstone, in Oxfordshire. Using our donation, TOE will be returning arable land to species-rich grassland, using locally sourced seed from a diverse meadow. Managing the project in a traditional manner with a mix of low-level grazing and hay cuts, this long-term project will secure a high-quality species rich meadow for at least the next 30 years.



“ We are setting the benchmark high for manufacturing to do its part in the overall reduction of environmental impact. Our investment in this new facility supports the promises we make to all our stakeholders by providing the very best platform for innovation in our products, but most importantly by doing it in a truly responsible and ethical way.

**Paul Smith, Group Quality & Regulatory Affairs Director, Owen Mumford** ”